Novo Nordisk rebounds
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback